The prenatal origins of cancer

Nature Reviews Cancer

Volumn 14, Issue 4, 2014, Pages 277-289

  Marshall, Glenn M ^a,b   Carter, Daniel R ^b   Cheung, Belamy B ^b   Liu, Tao ^b   Mateos, Marion K ^a,b   Meyerowitz, Justin G ^c   Weiss, William A ^c  

^a SYDNEY CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BETA CATENIN; BMI1 PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2C; EXCITATORY AMINO ACID TRANSPORTER 2; GA BINDING PROTEIN; IMMUNOGLOBULIN HEAVY CHAIN; MYC PROTEIN; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR RECEPTOR; PROTEIN P53; SIRTUIN 1; SIRTUIN 2; SODIUM GLUCOSE COTRANSPORTER 1; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR GATA 2; TRANSCRIPTION FACTOR GLI2; TRANSCRIPTION FACTOR MASH1; TRANSCRIPTION FACTOR OTX2; TRANSCRIPTION FACTOR RUNX1; TRANSFORMING GROWTH FACTOR BETA; TYROSINE 3 MONOOXYGENASE; WNT PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; B CELL LEUKEMIA; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CHILDHOOD CANCER; DOWN SYNDROME; EMBRYO DEVELOPMENT; GENE EXPRESSION PROFILING; GENE MUTATION; GENE REARRANGEMENT; GENETIC ASSOCIATION; GENOMIC INSTABILITY; HUMAN; LEUKEMOGENESIS; LOSS OF FUNCTION MUTATION; LYMPHOID PROGENITOR CELL; MALIGNANT TRANSFORMATION; MEDULLOBLASTOMA; MYELOID LEUKEMIA; MYELOPROLIFERATIVE DISORDER; NEUROBLASTOMA; NONHUMAN; PRENATAL PERIOD; PRIORITY JOURNAL; REVIEW; TRISOMY 21; WNT SIGNALING PATHWAY;

ANIMALS; B-LYMPHOCYTES; CARCINOGENESIS; CEREBELLAR NEOPLASMS; CHILD; DOWN SYNDROME; EMBRYO, MAMMALIAN; FEMALE; GENOMIC INSTABILITY; HUMANS; MEDULLOBLASTOMA; MUTATION; MYELOPROLIFERATIVE DISORDERS; NEURAL CREST; NEUROBLASTOMA; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREGNANCY;

EID: 84897440556     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3679     Document Type: Review

References (188)

1. Valent, P. et al. Cancer stem cell definitions and terminology: the devil is in the details. Nat. Rev. Cancer 12, 767-775 (2012).
2. Greaves, M. F., Maia, A. T., Wiemels, J. L. & Ford, A. M. Leukemia in twins: lessons in natural history. Blood 102, 2321-2333 (2003).
3. Eaton, K. W., Tooke, L. S., Wainwright, L. M., Judkins, A. R. & Biegel, J. A. Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors. Pediatr. Blood Cancer 56, 7-15 (2011).
4. Nuchtern, J. G. et al. A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study. Ann. Surg. 256, 573-580 (2012).
5. Beckwith, J. B. Precursor lesions of Wilms tumor: clinical and biological implications. Med. Pediatr. Oncol. 21, 158-168 (1993).
6. Cohnheim, J. Congenitales, quergestreiftes Muskelsarkom der Nieren. Virchows Archiv 65, 64-69 (in German) (1875).
7. Durante, F. Nesso fisio-patologico tra la struttura dei nei materni e la genesi di alcuni tumori maligni. Arch. Memo. Observ. Chir Prat 11, 217-226 (in Italian) (1874).
8. Virchow, R. Die multiloculäre, ulcerirende Echinokokkengeschwulst der Leber. Verhandlungen der Physicalisch-Medicinischen Gesellschaft, 6, 84-95 (in German) (1855).
9. Gruhn, B. et al. Prenatal origin of childhood acute lymphoblastic leukemia, association with birth weight and hyperdiploidy. Leukemia 22, 1692-1697 (2008).
10. Pine, S. R. et al. Incidence and clinical implications of G ATA 1 mutations in newborns with Down syndrome. Blood 110, 2128-2131 (2007)
11. Brodeur, G. M. Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer 3, 203-216 (2003).
12. Maris, J. M. Recent advances in neuroblastoma. New Engl. J. Med. 362, 2202-2211 (2010).
13. Huber, K. The sympathoadrenal cell lineage: specification, diversification, and new perspectives. Dev. Biol. 298, 335-343 (2006).
14. Zimmerman, K. A. et al. Differential expression of myc family genes during murine development. Nature 319, 780-783 (1986).
15. Hansford, L. M. et al. Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. Proc. Natl Acad. Sci. USA 101, 12664-12669 (2004).
16. Wartiovaara, K., Barnabe-Heider, F., Miller, F. D. & Kaplan, D. R. N-myc promotes survival and induces S-phase entry of postmitotic sympathetic neurons. J. Neurosci. 22, 815-824 (2002).
17. Yuan, J. & Yankner, B. A. Apoptosis in the nervous system. Nature 407, 802-809 (2000).
18. Zhu, S. et al. Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. Cancer Cell 21, 362-373 (2012).
19. Calao, M. et al. Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation. Oncogene 32, 3616-3626 (2013).
20. Weiss, W. A., Aldape, K., Mohapatra, G., Feuerstein, B. G. & Bishop, J. M. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J. 16, 2985-2995 (1997).
21. Marshall, G. M. et al. SIRT1 promotes N-Myc oncogenesis through a positive feedback loop involving the effects of MKP3 and ERK on N-Myc protein stability. PLoS Genet. 7, e1002135 (2011).
22. Liu, P. Y. et al. The histone deacetylase SIRT2 stabilizes Myc oncoproteins. Cell Death Differ. 20, 503-514 (2013).
23. Murphy, D. J. et al. Distinct thresholds govern Myc's biological output in vivo. Cancer Cell 14, 447-457 (2008).
24. F1174L mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell 22, 117-130 (2012).
25. Reissmann, E. et al. Involvement of bone morphogenetic protein-4 and bone morphogenetic protein-7 in the differentiation of the adrenergic phenotype in developing sympathetic neurons. Development 122, 2079-2088 (1996).
26. Schneider, C., Wicht, H., Enderich, J., Wegner, M. & Rohrer, H. Bone morphogenetic proteins are required in vivo for the generation of sympathetic neurons. Neuron 24, 861-870 (1999).
27. Mosse, Y. P. et al. Germline PHOX2B mutation in hereditary neuroblastoma. Am. J. Hum. Genet. 75, 727-730 (2004).
28. Trochet, D. et al. Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Am. J. Hum. Genet. 74, 761-764 (2004).
29. Bourdeaut, F. et al. Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Cancer Lett. 228, 51-58 (2005).
30. Reiff, T. et al. Neuroblastoma phox2b variants stimulate proliferation and dedifferentiation of immature sympathetic neurons. J. Neurosci. 30, 905-915 (2010).
31. Alam, G. et al. MYCN promotes the expansion of Phox2B-positive neuronal progenitors to drive neuroblastoma development. Am. J. Pathol. 175, 856-866 (2009).
32. Rybak, A. et al. A feedback loop comprising lin-28 and let-7 controls pre-let-7 maturation during neural stem-cell commitment. Nature Cell Biol. 10, 987-993 (2008).
33. Molenaar, J. J. et al. LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nature Genet. 44, 1199-1206 (2012).
34. Yu, J. et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 318, 1917-1920 (2007).
35. Balzer, E., Heine, C., Jiang, Q., Lee, V. M. & Moss, E. G. LIN28 alters cell fate succession and acts independently of the let-7 microRNA during neurogliogenesis in vitro. Development 137, 891-900 (2010).
36. Murray, M. J. et al. LIN28 Expression in malignant germ cell tumors downregulates let-7 and increases oncogene levels. Cancer Res. 73, 4872-4884 (2013).
37. Reiff, T. et al. Midkine and Alk signaling in sympathetic neuron proliferation and neuroblastoma predisposition. Development 138, 4699-4708 (2011).
38. Cheng, L. Y. et al. Anaplastic lymphoma kinase spares organ growth during nutrient restriction in Drosophila. Cell 146, 435-447 (2011).
39. Mosse, Y. P. et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455, 930-935 (2008).
40. Janoueix-Lerosey, I. et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455, 967-970 (2008).
41. Chen, Y. Y. et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455, 971-974 (2008).
42. De Brouwer, S. et al. Meta-Analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin. Cancer Res. 16, 4353-4362 (2010).
43. Heukamp, L. C. et al. Targeted expression of mutated ALK induces neuroblastoma in transgenic mice. Sci. Transl. Med. 4, ra91 (2012).
44. Schulte, J. H. et al. MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells. Oncogene 21, 1059-1065 (2012).
45. De Preter, K. et al. Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes. Genome Biol. 7, 17 (2006).
46. Beckwith, J. B. & Perrin, E. V. In situ neuroblastomas: a contribution to the natural history of neural crest tumors. Am. J. Pathol. 43, 1089-1104 (1963).
47. Woods, W. G. et al. A population-based study of the usefulness of screening for neuroblastoma. Lancet 348, 1682-1687 (1996).
48. Murtaza, M. et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497, 108-112 (2013).
49. Roy, A., Roberts, I., Norton, A. & Vyas, P. Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis. Br. J. Haematol. 147, 3-12 (2009).
50. Brodeur, G. M., Dahl, G. V., Williams, D. L., Tipton, R. E. & Kalwinsky, D. K. Transient leukemoid reaction and trisomy 21 mosaicism in a phenotypically normal newborn. Blood 55, 691-693 (1980).
51. Hasle, H. et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 17, 277-282 (2003).
52. Massey, G. V. et al. A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. Blood 107, 4606-4613 (2006).
53. Klusmann, J. H. et al. Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood 111, 2991-2998 (2008).
54. Tunstall-Pedoe, O. et al. Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of G ATA 1 mutations. Blood 112, 4507-4511 (2008).
55. Polski, J. M. et al. Acute megakaryoblastic leukemia after transient myeloproliferative disorder with clonal karyotype evolution in a phenotypically normal neonate. J. Pediatr. Hematol. Oncol. 24, 50-54 (2002).
56. Maclean, G. A. et al. Altered hematopoiesis in trisomy 21 as revealed through in vitro differentiation of isogenic human pluripotent cells. Proc. Natl Acad. Sci. USA 109, 17567-17572 (2012).
57. Chou, S. T. et al. Trisomy 21-Associated defects in human primitive hematopoiesis revealed through induced pluripotent stem cells. Proc. Natl Acad. Sci. USA 109, 17573-17578 (2012).
58. Kirsammer, G. et al. Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome. Blood 111, 767-775 (2008).
59. Dore, L. C. & Crispino, J. D. Transcription factor networks in erythroid cell and megakaryocyte development. Blood 118, 231-239 (2011).
60. Bourquin, J. P. et al. Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proc. Natl Acad. Sci. USA 103, 3339-3344 (2006).
61. Stankiewicz, M. J. & Crispino, J. D. ETS2 and ERG promote megakaryopoiesis and synergize with alterations in GATA-1 to immortalize hematopoietic progenitor cells. Blood 113, 3337-3347 (2009).
62. Salek-Ardakani, S. et al. ERG is a megakaryocytic oncogene. Cancer Res. 69, 4665-4673 (2009).
63. Birger, Y. et al. Perturbation of fetal hematopoiesis in a mouse model of Down syndrome's transient myeloproliferative disorder. Blood 122, 988-998 (2013).
64. Elagib, K. E. et al. RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation. Blood 101, 4333-4341 (2003).
65. Gurbuxani, S., Vyas, P. & Crispino, J. D. Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood 103, 399-406 (2004).
66. Taub, J. W. et al. Prenatal origin of G ATA 1 mutations may be an initiating step in the development of megakaryocytic leukemia in Down syndrome. Blood 104, 1588-1589 (2004).
67. Li, Z. et al. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nature Genet. 37, 613-619 (2005).
68. Hitzler, J. K., Cheung, J., Li, Y., Scherer, S. W. & Zipursky, A. G ATA 1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood 101, 4301-4304 (2003).
69. Rainis, L. et al. Mutations in exon 2 of G ATA 1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood 102, 981-986 (2003).
70. Alford, K. A. et al. Analysis of G ATA 1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia. Blood 118, 2222-2238 (2011).
71. Kanezaki, R. et al. Down syndrome and G ATA 1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia. Blood 116, 4631-4638 (2010).
72. Zipursky, A. Transient leukaemia-A benign form of leukaemia in newborn infants with trisomy 21. Br. J. Haematol. 120, 930-938 (2003).
73. Muramatsu, H. et al. Risk factors for early death in neonates with Down syndrome and transient leukaemia. Br. J. Haematol. 142, 610-615 (2008).
74. Roy, A. et al. Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21. Proc. Natl Acad. Sci. USA 109, 17579-17584 (2012).
75. Woo, A. J. et al. Developmental differences in IFN signaling affect GATA1s-induced megakaryocyte hyperproliferation. J. Clin. Invest. 123, 3292-3304 (2013).
76. Nikolaev, S. I. et al. Exome sequencing identifies putative drivers of progression of transient myeloproliferative disorder to AMKL in infants with Down syndrome. Blood 122, 554-561 (2013).
77. Saida, S. et al. Clonal selection in xenografted TAM recapitulates the evolutionary process of myeloid leukemia in Down syndrome. Blood 121, 4377-4387 (2013).
78. Roberts, I. et al. GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia. Blood 122, 3908-3917 (2013).
79. Ford, A. M. et al. In utero rearrangements in the trithorax-related oncogene in infant leukaemias. Nature 363, 358-360 (1993).
80. Wiemels, J. L. et al. Prenatal origin of acute lymphoblastic leukaemia in children. Lancet 354, 1499-1503 (1999).
81. Teuffel, O. et al. Prenatal origin of separate evolution of leukemia in identical twins. Leukemia 18, 1624-1629 (2004).
82. Taub, J. W. et al. High frequency of leukemic clones in newborn screening blood samples of children with B-precursor acute lymphoblastic leukemia. Blood 99, 2992-2996 (2002).
83. Eguchi-Ishimae, M. et al. Breakage and fusion of the TEL (ETV6) gene in immature B lymphocytes induced by apoptogenic signals. Blood 97, 737-743 (2001).
84. McHale, C. M. et al. Prenatal origin of ETV6-RUNX1-positive acute lymphoblastic leukemia in children born in California. Genes Chromosomes Cancer 37, 36-43 (2003).
85. Olsen, M. et al. Preleukemic TEL-AML1-positive clones at cell level of 10(-3) to 10(-4) do not persist into adulthood. J. Pediatr. Hematol.Oncol. 28, 734-740 (2006).
86. Hong, D. et al. Initiating and cancer-propagating cells in TEL-AML1-Associated childhood leukemia. Science 319, 336-339 (2008).
87. Tuszuki, S. & Seto, M. TEL (ETV6)-AML1 (RUNX1) initiates self-renewing fetal pro-B cells in association with a transcriptional program shared with embryonic stem cells in mice. Stem Cells 31, 236-247 (2013).
88. Torrano, V., Procter, J., Cardus, P., Greaves, M. & Ford, A. M. ETV6-RUNX1 promotes survival of early B lineage progenitor cells via a dysregulated erythropoietin receptor. Blood 118, 4910-4918 (2011).
89. van der Weyden, L. et al. Modeling the evolution of ETV6-RUNX1-induced B-cell precursor acute lymphoblastic leukemia in mice. Blood 118, 1041-1051 (2011).
90. Ford, A. M. et al. The TEL-AML1 leukemia fusion gene dysregulates the TGF-β pathway in early B lineage progenitor cells. J. Clin. Invest. 119, 826-836 (2009).
91. + acute lymphoblastic leukemia. Blood 118, 5559-5564 (2011).
92. Chuk, M. K., McIntyre, E., Small, D. & Brown, P. Discordance of MLL-rearranged (MLL-R) infant acute lymphoblastic leukemia in monozygotic twins with spontaneous clearance of preleukemic clone in unaffected twin. Blood 113, 6691-6694 (2009).
93. Powell, B. C. et al. Identification of TP53 as an acute lymphocytic leukemia susceptibility gene through exome sequencing. Pediatr. Blood Cancer 60, E1-E3 (2013).
94. Holmfeldt, L. et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nature Genet. 45, 242-252 (2013).
95. Ito, M. Control of mental activities by internal models in the cerebellum. Nature Rev. Neurosci. 9, 304-313 (2008).
96. Simeone, A., Acampora, D., Gulisano, M., Stornaiuolo, A. & Boncinelli, E. Nested expression domains of four homeobox genes in developing rostral brain. Nature 358, 687-690 (1992).
97. Wingate, R. J. & Hatten, M. E. The role of the rhombic lip in avian cerebellum development. Development 126, 4395-4404 (1999).
98. Adamson, D. C. et al. OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas. Cancer Res. 70, 181-191 (2010).
99. Bai, R. Y., Staedtke, V., Lidov, H. G., Eberhart, C. G. & Riggins, G. J. OTX2 represses myogenic and neuronal differentiation in medulloblastoma cells. Cancer Res. 72, 5988-6001 (2012).
100. Bunt, J. et al. OTX2 directly activates cell cycle genes and inhibits differentiation in medulloblastoma cells. Int. J. Cancer 131, E21-E32 (2012).
101. Hatten, M. E. & Heintz, N. Mechanisms of neural patterning and specification in the developing cerebellum. Annu. Rev. Neurosci. 18, 385-408 (1995).
102. Morales, D. & Hatten, M. E. Molecular markers of neuronal progenitors in the embryonic cerebellar anlage. J. Neurosci. 26, 12226-12236 (2006).
103. Spassky, N. et al. Primary cilia are required for cerebellar development and Shh-dependent expansion of progenitor pool. Dev. Biol. 317, 246-259 (2008).
104. Chang, C. H., Chang, F. M., Yu, C. H., Ko, H. C. & Chen, H. Y. Assessment of fetal cerebellar volume using three-dimensional ultrasound. Ultrasound Med. Biol. 26, 981-988 (2000).
105. Volpe, J. J. Cerebellum of the premature infant: rapidly developing, vulnerable, clinically important. J. Child Neurol. 24, 1085-1104 (2009).
106. Andersen, B. B., Korbo, L. & Pakkenberg, B. A quantitative study of the human cerebellum with unbiased stereological techniques. J. Comparative Neurol. 326, 549-560 (1992).
107. Dahmane, N. & Ruiz i Altaba, A. Sonic hedgehog regulates the growth and patterning of the cerebellum. Development 126, 3089-3100 (1999).
108. Lee, A. et al. Isolation of neural stem cells from the postnatal cerebellum. Nature Neurosci. 8, 723-729 (2005).
109. Wang, V. Y., Rose, M. F. & Zoghbi, H. Y. Math1 expression redefines the rhombic lip derivatives and reveals novel lineages within the brainstem and cerebellum. Neuron 48, 31-43 (2005).
110. Raaf, J. & Kernohan, J. W. A study of the external granular layer in the cerebellum. The disappearance of the external granular layer and the growth of the molecular and internal granular layers in the cerebellum. Am. J. Anat. 75, 151-172 (1944).
111. Gailani, M. R. et al. Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromosome 9. Cell 69, 111-117 (1992).
112. Hahn, H. et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 85, 841-851 (1996).
113. Northcott, P. A. et al. Medulloblastoma comprises four distinct molecular variants. J. Clin. Oncol. 29, 1408-1414 (2011).
114. Goodrich, L. V., Milenkovic, L., Higgins, K. M. & Scott, M. P. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 277, 1109-1113 (1997).
115. Brugieres, L. et al. Incomplete penetrance of the predisposition to medulloblastoma associated with germ-line SUFU mutations. J. Med. Genet. 47, 142-144 (2010).
116. Northcott, P. A. et al. Subgroup-specific structural variation across 1, 000 medulloblastoma genomes. Nature 488, 49-56 (2012).
117. Thomas, W. D. et al. Patched1 deletion increases N-Myc protein stability as a mechanism of medulloblastoma initiation and progression. Oncogene 28, 1605-1615 (2009).
118. Hallahan, A. R. et al. The SmoA1 mouse model reveals that Notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res. 64, 7794-7800 (2004).
119. Mao, J. et al. A novel somatic mouse model to survey tumorigenic potential applied to the Hedgehog pathway. Cancer Res. 66, 10171-10178 (2006).
120. Weiner, H. L. et al. Induction of medulloblastomas in mice by sonic hedgehog, independent of Gli1. Cancer Res. 62, 6385-6389 (2002).
121. Schuller, U. et al. Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. Cancer Cell 14, 123-134 (2008).
122. Yang, Z. J. et al. Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells. Cancer Cell 14, 135-145 (2008).
123. Knoepfler, P. S., Cheng, P. F. & Eisenman, R. N. N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation. Genes Dev. 16, 2699-2712 (2002).
124. Browd, S. R. et al. N-myc can substitute for insulin-like growth factor signaling in a mouse model of sonic hedgehog-induced medulloblastoma. Cancer Res. 66, 2666-2672 (2006).
125. Korshunov, A. et al. Biological and clinical heterogeneity of MYCN-Amplified medulloblastoma. Acta Neuropathol. 123, 515-527 (2012).
126. Swartling, F. J. et al. Pleiotropic role for MYCN in medulloblastoma. Genes Dev. 24, 1059-1072 (2010).
127. Kawauchi, D. et al. A mouse model of the most aggressive subgroup of human medulloblastoma. Cancer Cell 21, 168-180 (2012).
128. Pei, Y. et al. An animal model of MYC-driven medulloblastoma. Cancer Cell 21, 155-167 (2012).
129. Kool, M. et al. Molecular subgroups of medulloblastoma: an international meta-Analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol. 123, 473-484 (2012).
130. Pei, Y. et al. WNT signaling increases proliferation and impairs differentiation of stem cells in the developing cerebellum. Development 139, 1724-1733 (2012).
131. Kropilak, M., Jagelman, D. G., Fazio, V. W., Lavery, I. L. & McGannon, E. Brain tumors in familial adenomatous polyposis. Diseases Colon Rectum 32, 778-782 (1989).
132. Taylor, M. D. et al. Failure of a medulloblastoma-derived mutant of SUFU to suppress WNT signaling. Oncogene 23, 4577-4583 (2004).
133. Robinson, G. et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 488, 43-48 (2012).
134. Barker, N. et al. The chromatin remodelling factor Brg-1 interacts with β-catenin to promote target gene activation. EMBO J. 20, 4935-4943 (2001).
135. Pugh, T. J. et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 488, 106-110 (2012).
136. Momota, H., Shih, A. H., Edgar, M. A. & Holland, E. C. c-Myc and β-catenin cooperate with loss of p53 to generate multiple members of the primitive neuroectodermal tumor family in mice. Oncogene 27, 4392-4401 (2008).
137. Gibson, P. et al. Subtypes of medulloblastoma have distinct developmental origins. Nature 468, 1095-1099 (2010).
138. Takebayashi, H. et al. Non-overlapping expression of Olig3 and Olig2 in the embryonic neural tube. Mech. Dev. 113, 169-174 (2002).
139. Taylor, M. D. et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 123, 465-472 (2012).
140. Swartling, F. J. et al. Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. Cancer Cell 21, 601-613 (2012).
141. Stehelin, D., Varmus, H. E., Bishop, J. M. & Vogt, P. K. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature 260, 170-173 (1976).
142. Siddhartha, M. The Emperor of All Maladies: A Biography of Cancer (Scribner, 2010)
143. Knudson, A. G. Jr Mutation and cancer: statistical study of retinoblastoma. Proc. Natl Acad. Sci. USA 68, 820-823 (1971).
144. Stephens, P. J. et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144, 27-40 (2011).
145. Forment, J. V., Kaidi, A. & Jackson, S. P. Chromothripsis and cancer: causes and consequences of chromosome shattering. Nat. Rev. Cancer 12, 663-670 (2012).
146. Molenaar, J. J. et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 483, 589-593 (2012).
147. Otto, T. et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 15, 67-78 (2009).
148. Masciari, S. et al. F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome. JAMA 299, 1315-1319 (2008).
149. Custodio, G. et al. Impact of neonatal screening and surveillance for the TP53 R337H mutation on early detection of childhood adrenocortical tumors. J. Clin. Oncol. 31, 2619-2626 (2013).
150. Yoshimoto, M. et al. Embryonic day 9 yolk sac and intra-embryonic hemogenic endothelium independently generate a B-1 and marginal zone progenitor lacking B-2 potential. Proc. Natl Acad. Sci. USA 108, 1468-1473 (2011).
151. Hardy, R. R. B-1 B cell development. J. Immunol. 177, 2749-2754 (2006).
152. Montecino-Rodriguez, E. & Dorshkind, K. Formation of B-1 B cells from neonatal B-1 transitional cells exhibits NF-kB redundancy. J. Immunol. 187, 5712-5719 (2011).
153. + lympho-myeloid stem cells lacking erythro-megakaryocytic potential a revised road map for adult blood lineage commitment. Cell 121, 295-306 (2005).
154. Li, Y. S., Wasserman, R., Hayakawa, K. & Hardy, R. R. Identification of the earliest B lineage stage in mouse bone marrow. Immunity 5, 527-535 (1996).
155. - early B cell precursors. J. Exp. Med. 203, 675-687 (2006).
156. Sitnicka, E. et al. Complementary signaling through flt3 and interleukin-7 receptor α is indispensable for fetal and adult B cell genesis. J. Exp. Med. 198, 1495-1506 (2003).
157. Sitnicka, E. et al. Key role of flt3 ligand in regulation of the common lymphoid progenitor but not in maintenance of the hematopoietic stem cell pool. Immunity 17, 463-472 (2002).
158. Nutt, S. L. & Kee, B. L. The transcriptional regulation of B cell lineage commitment. Immunity 26, 715-725 (2007).
159. Kirstetter, P., Thomas, M., Dierich, A., Kastner, P. & Chan, S. Ikaros is critical for B cell differentiation and function. Eur. J. Immunol. 32, 720-730 (2002).
160. Wang, J. H. et al. Selective defects in the development of the fetal and adult lymphoid system in mice with an Ikaros null mutation. Immunity 5, 537-549 (1996).
161. Yoshida, T., Ng, S. Y., Zuniga-Pflucker, J. C. & Georgopoulos, K. Early hematopoietic lineage restrictions directed by Ikaros. Nature Immunol. 7, 382-391 (2006).
162. Mullighan, C. G. et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453, 110-114 (2008).
163. Cobaleda, C., Jochum, W. & Busslinger, M. Conversion of mature B cells into T cells by dedifferentiation to uncommitted progenitors. Nature 449, 473-477 (2007).
164. Mullighan, C. G. et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446, 758-764 (2007).
165. Shah, S. et al. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nature Genet. 45, 1226-1231 (2013).
166. Bain, G. et al. Both E12 and E47 allow commitment to the B cell lineage. Immunity 6, 145-154 (1997).
167. Borghesi, L. et al. E47 is required for V(D)J recombinase activity in common lymphoid progenitors. J. Exp. Med. 202, 1669-1677 (2005).
168. Welinder, E. et al. The transcription factors E2A and HEB act in concert to induce the expression of FOXO1 in the common lymphoid progenitor. Proc. Natl Acad. Sci. USA 108, 17402-17407 (2011).
169. Kikuchi, K., Kasai, H., Watanabe, A., Lai, A. Y. & Kondo, M. IL-7 specifies B cell fate at the common lymphoid progenitor to pre-proB transition stage by maintaining early B cell factor expression. J. Immunol. 181, 383-392 (2008).
170. Seo, W., Ikawa, T., Kawamoto, H. & Taniuchi, I. Runx1-Cbfβ facilitates early B lymphocyte development by regulating expression of Ebf1. J. Exp. Med. 209, 1255-1262 (2012).
171. Growney, J. D. et al. Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood 106, 494-504 (2005).
172. Tsubono, Y. & Hisamichi, S. A halt to neuroblastoma screening in Japan. New Engl. J. Med. 350, 2010-2011 (2004).
173. Breslow, N., Olshan, A., Beckwith, J. B. & Green, D. M. Epidemiology of Wilms tumor. Med. Pediatr. Oncol. 21, 172-181 (1993).
174. Coppes, M. J., Haber, D. A. & Grundy, P. E. Genetic events in the development of Wilms' tumor. N. Engl. J. Med. 331, 586-590 (1994).
175. Park, S. et al. Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour. Nature Genet. 5, 363-367 (1993).
176. Chen, D. et al. Cell-specific effects of RB or RB/p107 loss on retinal development implicate an intrinsically death-resistant cell-of-origin in retinoblastoma. Cancer Cell 5, 539-551 (2004).
177. Zhang, J., Schweers, B. & Dyer, M. A. The first knockout mouse model of retinoblastoma. Cell Cycle 3, 952-959 (2004).
178. Federico, S., Brennan, R. & Dyer, M. A. Childhood cancer and developmental biology a crucial partnership. Curr. Top. Dev. Biol. 94, 1-13 (2011).
179. Abramson, D. H. et al. Rapid growth of retinoblastoma in a premature twin. Arch. Ophthalmol. 120, 1232-1233 (2002).
180. Lohmann, D. R. & Gallie, B. L. Retinoblastoma: revisiting the model prototype of inherited cancer. Am. J. Med. Genet. C. Semin. Med. Genet. 129C, 23-28 (2004).
181. Looijenga, L. H. & Oosterhuis, J. W. Pathogenesis of testicular germ cell tumours. Rev. Reprod. 4, 90-100 (1999).
182. Bussey, K. J. et al. Chromosome abnormalities of eighty-one pediatric germ cell tumors: sex-, age-, site-, and histopathology-related differences-A Children's Cancer Group study. Genes Chromosomes Cancer 25, 134-146 (1999)
183. Isaacs, H. Jr. Perinatal (fetal and neonatal) germ cell tumors. J. Pediatr. Surg. 39, 1003-1013 (2004).
184. Schindler, J. W. et al. TEL-AML1 corrupts hematopoietic stem cells to persist in the bone marrow and initiate leukemia. Cell Stem Cell 5, 43-53 (2009).
185. Klochendler-Yeivin, A. et al. The murine SNF5/INI1 chromatin remodeling factor is essential for embryonic development and tumor suppression. EMBO Rep. 1, 500-506 (2000).
186. Versteege, I. et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394, 203-206 (1998).
187. Biegel, J. A. et al. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res. 59, 74-79 (1999).
188. Sevenet, N. et al. Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers. Am. J. Hum. Genet. 65, 1342-1348 (1999).